Hansa Biopharma

Joint Global Coordinator & Joint Bookrunner

Van Lanschot Kempen acted as Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma

Transaction Highlights

Capital increase via a PIPE of 7,848,111 new ordinary shares, generating gross proceeds of SEK 416m (€38.2m) for Hansa Biopharma
Investors subscribed in the PIPE for SEK 53 per new share which is in line with the five day VWAP prior to the announcement of the deal
The capital increase included participation from existing institutional investor Redmile and new investor Braidwell, along with participation from other U.S. and international institutional investors
The transaction proceeds will be used to support the commercialization of imlifidase in kidney transplantation, and further R&D activities
Van Lanschot Kempen also acted as Joint Global Coordinator and Joint Bookrunner on Hansa Biopharma’s SEK 1.1bn capital increase in 2020
This transaction marks Van Lanschot Kempen’s 10^thECM transaction for a Nordic company in the last six months, underpinning the ability of Van Lanschot Kempen to support companies in the Nordics across sectors

Company description

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program based on the company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA.

Background Van Lanschot Kempen Life Sciences & Healthcare

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80m PIPE
Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
Joint Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank (EIB)
Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150 million PIPE and a SEK 50 million Fully Guaranteed Rights Issue by Abliva
Joint Global Coordinator & Joint Bookrunner in the SEK 150 million Fully Guaranteed Rights Issue by SynAct Pharma
Financial adviser in the spin-out and Capital Increase of InnoSIGN
Co-Manager in the USD 806 million Capital Increase by argenx
Sole Block Placing Agent in the placement of 1.4 and 1.3 million Molecular Partners shares
Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp

Please do not hesitate to contact us if you have further questions

Nadine Maalouf

n.maalouf@vanlanschotkempen.com

Robin van Wijk

r.vanwijk@vanlanschotkempen.com